Favorable outcomes of localized synovial sarcoma patients with a high utilization rate of neoadjuvant and/or adjuvant chemotherapy
Favorable outcomes of localized synovial sarcoma patients with a high utilization rate of neoadjuvant and/or adjuvant chemotherapy
复制标题
DOI：
10.3892/mco.2019.1863
复制
发表时间：
2019-08-01
影响因子：
1.2
通讯作者：
Yoshikawa, Hideki
中科院分区：
文献类型：
--
作者：
Outani, Hidetatsu;Kakunaga, Shigeki;Yoshikawa, Hideki
滑膜肉瘤（SS）被认为是一种化学敏感的软组织肉瘤。因此，新辅助和/或辅助化疗（N/AC）用于治疗高危SS患者。然而，N/AC的作用仍然存在争议。本研究旨在回顾手术治疗局限性SS的临床结果，并通过长期观察研究N/AC的影响。回顾性分析54例手术治疗的局限性SS患者的临床结果。患者的中位年龄为42岁（范围：8-81岁），存活者的中位随访期为94个月（范围：7-220个月）。共有38例患者（70%）接受了化疗。其中，32例（59%）患者接受了新辅助化疗，33例（61%）患者接受了辅助化疗，27例（50%）患者接受了新辅助和辅助化疗。14例患者（26%）接受了辅助放疗。3例（6%）局部复发，13例（24%）发生远处转移。5年和10年的总生存率（OS）分别为87%和84%。N/AC没有改善生存率。总之，我们发现N/AC利用率高的患者的长期OS令人满意。应进一步研究，以评估哪些SS人群将受益于N/AC。
Synovial sarcoma (SS) is considered to be a chemosensitive, soft tissue sarcoma. Therefore, neoadjuvant and/or adjuvant chemotherapy (N/AC) is used for the treatment of high-risk SS patients. However, the role of N/AC remains controversial. The present study aimed to review the clinical outcomes of surgically treated localized SS and investigate the effects of N/AC with long-term observation. The clinical outcomes of 54 patients with surgically treated localized SS were retrospectively analyzed. The median patient age was 42 years (range, 8-81 years), and the median follow-up period was 94 months for survivors (range, 7-220 months). A total of 38 patients (70%) received chemotherapy. Of these, 32 (59%) patients received neoadjuvant chemotherapy, 33 (61%) received adjuvant chemotherapy, and 27 (50%) received neoadjuvant and adjuvant chemotherapy. Fourteen patients (26%) received adjuvant radiotherapy. Three patients (6%) had local recurrence and 13 patients (24%) developed distant metastasis. The overall survival (OS) rates at 5 and 10 years were 87 and 84%, respectively. N/AC did not improve survival. In conclusion, we found satisfactory long-term OS among patients with a high utilization rate of N/AC. Further study should be necessary to evaluate which population of SS would benefit from N/AC.